Introduction
Stargardt disease (STGD), originally described in 1909, is an autosomal recessive condition of childhood, characterised by a bilateral loss of central vision over a period of several months. 1 This frequent cause of macular degeneration in children accounts for about 7% of all retinal dystrophies. 2 It has an early onset (between 7 and 12 years of age), a rapidly progressive course and a poor final visual outcome. The final visual acuity ranges from 1/60 to 3/60 and the peripheral visual field remains normal throughout life.
The STGD gene has been mapped to the short arm of chromosome 1 3 in a narrow genetic interval, subsequently assigned to band p22. 1 . 4 In addition, we have provided evidence of genetic homogeneity of the disease. 3 On the other hand, in 1965, Franceschetti described another form of fleck fundus disease termed late-onset fundus flavimaculatus (FFM) 5 with a Stargardt-like phenotype, but differing by a late-onset, more slowly progressive course and better prognosis. The decrease of vision is gradual and slowly progressive over many years, with a final visual acuity of 1/60-6/60. When visual acuity loss begins in the first two decades the disease is termed STGD, while the term 'FFM' is favoured when the disease begins later in life and has a slowly progressive course. 6 Yet the two conditions have long been regarded as varying manifestations of the same disease. Indeed, the FFM gene has been mapped to the STGD locus, supporting the view that the two conditions are allelic disorders. 7 Moreover, owing to the broad spectrum of age of onset in FFM (17 to 63 years), this genetic mapping addressed the intriguing question of the relevance of this locus in age-related macular degenerations (AMD) and, more generally, of a possible continuum of macular disorders at this locus from early childhood to old age. 7 Mutations in the photoreceptor cell-specific ATPbinding transporter (ABCR) gene have been recently reported in STGD. 8 The ATP-Binding Cassette (ABC) family, also called 'traffic ATPases', belongs to a superfamily of membrane proteins involved in the energy-dependent transport of a wide variety of substrates across membranes 8, 9 and the ABCR mouse orthologue has been identified (photoreceptor rim protein : RmP). 10 In addition, Allikmets et al reported on heterozygous ABCR gene mutations in age-related macular degenerations (AMD), 11 the most frequent cause of blindness after 70 years of age. Here we report on the screening of the 50 ABCR exons 12 in 55 unrelated STGD and FFM families. Preliminary results suggest that truncating ABCR mutations resulted in a Stargardt phenotype whereas they were consistently absent in our series of FFM patients.
Patients and Methods

Patients
A total of 58 patients belonging to 55 unrelated families were split into two groups based on their age at onset of the disease (STGD before 12 years, FFM after 17 years). Among them, 40 families had STGD (15 multiplex families) and 15 families had late-onset FFM (four multiplex families). Ophthalmological data were available for each affected individual. The time course of the disease over approximately 10 years (1-40 years) was obtained by interviewing the patients or their parents and a pedigree was established. The minimal criteria for diagnosis of STGD and FFM have been previously described. 3, 7 Only 34/110 living parents were older than 60 and 49/220 living grand-parents were older than 70. Among them, 1/34 parent and 2/49 grand-parents were known to be affected with AMD.
Methods
For single strand conformation polymorphism analysis and direct sequencing of the 50 exons of the ABCR gene, genomic DNA (200 ng) was submitted to PCR amplification using 1 µM of intronic primers 10 and alpha 33 P dCTP (0.1 µl, 10 mCi/ml NEN) in an amplification mixture (20 µl) containing 200 mM dNTPs and 0.5 U Taq DNA polymerase (Life Technologies). Amplified DNA (2 µl) was mixed with an equal volume of formamide loading dye (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol), denatured for 10 min at 95°C, loaded on to a polyacrylamide gel (20 ϫ 45 ϫ 0.04 cm, MDE) and electrophoresed at room temperature for 14 h at 3 W. Gels were transferred on to 3 mm Whatman paper, dried and autoradiographed with Kodak X-OMAT films for 16-48 h.
For direct sequencing, amplification products were loaded on to a 0.7% agarose gel, purified by phenol-chloroform extraction and recovered by ethanol precipitation. Purified fragments were directly sequenced using the same specific intronic primers and the PRISM™ Ready Reaction Sequencing Kit (Perkin Elmer Cetus), on an automatic fluorometric DNA sequencer (Applied Biosystems).
Results
A total of 25 different mutations was identified in 21/40 STGD and 5/15 FFM patients, respectively. Interestingly, the truncating mutations (10/25) were identified in STGD only (3 nonsense, 2 frameshift and 5 splicing mutations, n = 11). In addition, 9 different missense mutations were detected in 10 additional STGD cases. Most of them (5/9) converted an arginine into an uncharged amino acid (Table 1 and Figure 1 ). By contrast, only missense mutations (n = 7) were identified in FFM patients (n = 5). All of them involved uncharged amino acids (4 leucines, 1 alanine and 2 glycines, Table 1 and Figure 1 ). On the other hand, all ABCR missense mutations identified in STGD and FFM concerned amino acids conserved in RmP 10 contrasting with the other members of the ABC family 8, 9 (see Table 1 ). So far, only two unrelated STGD patients were found to be homozygotes for a mutant genotype in our series (the 571-2A®G splice site mutation in intron 5 in a consanguineous family of Moroccan origin, an arginine to tryptophane substitution at codon 1640 in exon 35). The vast majority of our patients was either compound heterozygotes (5 STGD and 2 FFM) or heterozygotes for one single mutation (14 STGD and 3 FFM). None of these sequence changes have been previously reported 8 nor were they identified in any of 50 healthy controls (100 chromosomes).
It is worth noting that no mutation has been hitherto identified in the first family segregating both STGD and AMD in the patient and his mother, respectively. By contrast, in the second and third families, the grandmothers affected with AMD were found to carry one of the two different mutations identified in their grandsons affected with Stargardt disease (R1107C, family JUL; R212C, family JEG; see Table 1 ).
Discussion
The ABCR protein is a member of the adenosine triphosphate (ATP) binding cassette transporter superfamily 9 involved in transport of a wide variety of substrates across cellular membranes. Recently, Allikmets et al reported ABCR gene mutations in STGD. 8 The purpose of the present study was to investigate the allelic heterogeneity at the ABCR locus and to look for possible phenotype-genotype correlations in a large series of STGD/FFM patients.
Among the 25 hitherto unreported ABCR gene mutations described here, 10/25 were truncating mutations. Interestingly, mutations truncating the ABCR gene product were found in STGD patients only. In addition, all except one (HAD family) were either heterozygote for a frameshift mutation or compound heterozygote for frameshift and missense mutations. Based on this observation and on previously reported ABCR gene mutations in retinitis pigmentosa (RP) 14, 15 we suggest that homozygosity for truncating ABCR gene mutations results in RP phenotype, while compound heterozygosity for frameshift and missense mutations or two missense mutations at this locus results in STGD. Conversely, FFM phenotype is always the result of two missense mutations. Concerning the consanguineous STGD family with an homozygous splice site mutation (HAD, see Table 1 ), it is most likely that this mutation will not affect the reading frame.
Most of the missense mutations detected in STGD (5/9) converted charged into uncharged amino acids. By contrast, all mutations identified in FFM patients were missense mutations involving uncharged amino acids and none of them (except the A1038V mutation) were detected in STGD. Interestingly, the A1038V mutation was found in compound heterozygotes (one STGD, family CHE and one FFM, family VIL), the second mutation being another missense mutation in the FFM family (L541P) but a frameshift mutation in STGD (Table 1) . Furthermore, all ABCR missense mutations G3754T  E1252X  STGD  1  C3994T  Q1332X  STGD  1  C6337G  I2113X  STGD  1  JEG 2  C52T  R18W  IC  -+  STGD  1  C634T  R212C  EC  -+  STGD  5  GEN 2 , JEG 2  G1908T  Q636H  IC  -+  STGD  1  LOZ 2  C3056T  T1019M  IC  -+  STGD  1  C3322T  R1107C  IC  -+  STGD  1  JUL 2  C4916T  R1640W  IC  +  +  STGD  2  MAR 1  G5929A  G1977S  ATP2  +  +  STGD  1  GEN 2  G6320A  R2107H  IC  +  +  STGD  1  JUL 2   C3114T  A1038V  IC  -+  STGD  2  CHE 2  +FFM  +1  VII 2   T1622C  L541P  EC  -+  FFM  1  VII 2  T31C  L11P  IC  +  +  FFM  1  G3272A  G1090E  IC  +  +  FFM  1  G4522T  G1508C  IC  +  +  FFM  1  C5908T  L1970F  IC  +  +  FFM  1  GON 2  T5912G  L1971R  IC  +  +  FFM  1  GON 2 Mutations refer to the standard nomenclature. Truncating mutations are indicated by bold letters. EC: extracellular domain, IC: intracytoplasmic domain; ATP2: second ATP-binding site; RmP: mouse Rim protein, ABCs: other members of the ABC subfamily (mouse ABC1, mouse ABC2, human ABCC), +: conserved amino acid, -: non-conserved amino acid. The comment field indicates 1 homozygous families and 2 compound heterozygous families in which two independent altered alleles were identified.
detected in STGD and FFM patients involved amino acids conserved in the mouse ortholologue 10 , (see Table 1 ). Nevertheless, no correlation between the severity of the phenotype and the conservation of the mutated amino acid in other members of the ABC subfamily could be established. 8, 9 (see Table 1 ). On the other hand, it is worth noting that no mutation has been hitherto identified in 29/55 families with either STGD or FFM and that 17/26 patients were found to be heterozygotes for one single mutation (although 7/17 cases were multiplex, strongly suggesting an autosomal recessive inheritance). This point could be partly explained by the defective sensitivity of the PCR-SSCP method of detecting mutations (about 80%). 13 Nevertheless, it is also likely that some of the allelic mutations lie in an unscreened region of the gene, such as the introns or the promotor region. Finally, only two patients' relatives affected with AMD were found to carry an ABCR mutation identified in a STGD proband. It is particularly important to look for macular degeneration in parents and grandparents of STGD and FFM patients so as to decide whether the incidence of AMD in this subgroup is indeed higher than in a control population. 
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